CA-PATIENT-SAFETY
3.2.2020 15:02:07 CET | Business Wire | Press release
Patient Safety Movement Foundation is urging clinicians, patient advocates, hospitals and medical technology companies to support Data Sharing as part of the 2020 Federal Health IT plan.
“One of the key ways to combat preventable patient deaths in hospitals is for companies to share their data in a HIPAA compliant manner instead of hoarding it for profit. The plan proposed by the Office of the National Coordinator for Health Information Technology will help create the personalized patient data superhighway we need to reduce and eliminate preventable deaths in our hospitals,” said Joe Kiani, Founder of the Patient Safety Movement and Founder, Chairman, and CEO of Masimo. “If we block patient data, no one can create algorithms that can warn clinicians of potential problems before they happen. We are already losing way too many people to medical errors in our hospitals each year, and we can’t delay this any longer.”
Several years ago, a young man named Rory Staunton died of Sepsis because of exactly this type of fragmented medical information system. “On Tuesday, my son Rory was playing basketball at a school gym, fell and cut himself. His teacher put a bandaid on it. He died 5 days later from Sepsis,” said Orlaith Staunton. “Despite having a high heart rate for his size as measured by a patient monitor at his pediatrician’s office and a high white blood cell count that was detected in the Emergency Department’s blood test machine, Rory was sent home because no one had all of the details of his problems and care. They couldn’t put the high heart rate and high white blood cell count together with the full story to realize he had Sepsis. Had we had data sharing allowing a complete view of his history and condition or the benefit of a predictive algorithm to track my son’s case when he was connected to various monitors and blood test machines, he would probably be alive today.”
Since the founding of the Patient Safety Movement, nearly 100 companies have signed the voluntary Open Data Pledge, including Baxter, Cerner, Dräger, Edwards Lifesciences, GE Healthcare, IBM, Masimo, Medtronic, Oracle, Philips and Zoll. Complete list below. For more information on how you can sign the Pledge, please visit www.patientsafetymovement.org . For more information regarding the 2020 Federal Health IT Plan, please visit https://www.healthit.gov/sites/default/files/page/2020-01/2020-2025FederalHealthIT%20StrategicPlan_0.pdf .
Companies that have signed the Patient Safety Movement Foundation Open Data Pledge (alphabetical order):
AccuHealth Group |
Admetsys |
AirStrip |
Ambient Clinical |
Baxter |
BD Intelliport (formerly CRISI Medical Systems) |
Bernoulli Health |
Beterra Health |
BIOIN SOLUCIONES SAS |
Biovigil |
BrainStem Biometrics |
caresyntax, Inc. |
Cercacor |
Cerner |
Cheetah Medical, Inc. |
Clean Hands-Safe Hands |
CNSystems Medizintechnik AG |
Codonics |
CrossChx |
DebMed |
Decisio Health |
Deltex Medical |
Doctella |
Dräger |
DynaLabs LLC |
11 Health |
EarlySense |
eBroselow, LLC |
Edwards LifeSciences |
Forcare |
FUJIFILM SonoSite, Inc. |
GE Healthcare |
Genomi-k |
Hamilton Medical AG |
Handtevy-Pediatric Emergency Standards, Inc. |
Healthcentrix |
Heartin Inc. |
HeROScore |
Hiteks |
IBM Watson Health |
ICUcare |
Informs Inc. |
Innara Health |
Iradimed |
Jvion |
KnectIQ Inc. |
Kolkin |
LiDCO Group |
LumiraDX USA Inc. |
Magnamed Tecnologia Médica S/A. |
Masimo |
Mdoloris Medical Systems |
Medi+Sign |
Medical Simulation Corporation |
MediSafe Inc |
Medtronic |
Mindray |
Modulated Imaging |
Monarch Medical Technologies |
Neosim |
NeurOptics |
Oracle |
Patient Valet |
Pegwin |
PeraHealth |
PerceptiMed |
Philips Healthcare |
Phoenix Medical Systems Pvt. Ltd. |
Pieces Technology |
Pooyandegan Rah Saadat Co.,Ltd. |
Rapid Healthcare |
Redivus Health |
RGP Healthcare |
RightPatient |
RPRD Diagnostics |
SafeCare Group |
SafeStart Medical |
SenTec Inc. |
Smiths Medical |
Sotera Wireless |
Stanley Healthcare |
Stibo Systems |
SurgiCount Medical |
SwipeSense |
Talis Clinical |
ThermoMedics, Inc. |
Triton Electronic Systems LTD |
True Process |
Vitalacy (FORMERLY Hygenix) |
Welch Allyn (acquired by Hill-Rom) |
West-Com Nurse Call Systems, Inc |
ZOLL Medical |
About Patient Safety Movement Foundation
Each year, more than 200,000 people die unnecessarily in U.S. hospitals. Worldwide, 4.8 million lives are similarly lost. The Patient Safety Movement Foundation (PSMF) is a global non-profit that offers free tools to help achieve ZERO preventable deaths from hospital errors. The Patient Safety Movement Foundation was established through the support of the Masimo Foundation for Ethics, Innovation, and Competition in Healthcare to reduce that number of preventable deaths to ZERO. Improving patient safety requires a collaborative effort from all stakeholders, including patients, healthcare providers, medical technology companies, government, employers, and private payers. PSMF’s World Patient Safety, Science & Technology Summit brings together the world’s best minds for thought-provoking discussions and new ideas to challenge the status quo. Our Actionable Patient Safety Solutions (APSS) provide evidence-based processes to help hospitals eliminate errors. Our Open Data Pledge encourages healthcare technology companies to share the data for which their products are purchased. Visit patientsafetymovement.org.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200203005118/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Buys Back Shares Worth CHF 232 Million in the Context of Accelerated Bookbuild Offering11.3.2026 07:00:00 CET | Press release
Ad hoc announcement pursuant to Art. 53 LR Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that it has agreed to repurchase 1.6 million shares at a price of CHF 143.75 per share for a total consideration of CHF 232 million in the context of the accelerated bookbuild offering (“ABO”) of Galderma shares by Sunshine SwissCo GmbH (“EQT”), Abu Dhabi Investment Authority (Private Equities Department) and Auba Investment Pte. Ltd. (all together the “Selling Shareholders”) launched yesterday evening. The repurchase was made at the same price per share determined by the bookbuilding offering. As a result of yesterday evening’s ABO, the Selling Shareholders have fully divested their remaining stake in Galderma. The repurchase, which is expected to settle on March 13 is being financed by Galderma’s existing liquidity on hand and will not affect the company’s ability to deliver on its strategic and financing priorities. The shares will be held in treasury for futur
Thales Launches SkyDefender: The Integral Air and Missile Defence Dome With Artificial Intelligence11.3.2026 07:00:00 CET | Press release
SkyDefender is a multi-layer, multi-domain Integrated Air and Missile Defence system providing full protection against all types of air threats, on land, at sea and in space. SkyDefender integrates a network of advanced sensors and effectors with a versatile command and control (C2) system. With its open and modular architecture, it is fully compatible with existing air defence systems. Combining Thales’ expertise in cybersecurity and advanced artificial intelligence through cortAIx, Thales AI accelerator, SkyDefender enables operational superiority and proactive defence against cyberattacks and evolving threats. Thales is capable of delivering this critical protection globally from today. As air and missile threats are evolving faster than ever, from slow-moving drones to hypersonic missiles, attacks are becoming increasingly complex, saturating and unpredictable. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260310398606/
Curatis and Neupharma Announce Exclusive Licensing Agreement to Develop and Market Corticorelin (C-PTBE-01) for the Treatment of Peritumoral Brain Edema in Japan11.3.2026 07:00:00 CET | Press release
Japan is one of the world's most important pharmaceutical markets after the US and Europe. Neupharma’s team has extensive experience in developing and successfully commercialising orphan drugs as well as speciality care medicines in Japan, including a blockbuster drug. The agreement with Neupharma includes upfront and milestone payments of up to CHF 83.5 million as well as royalties of up to 20% on sales. The population of available patients eligible for corticorelin treatment associated with peritumoral brain edema is estimated at 60,000 in Japan and 500,000 worldwide. Global market potential is forecasted to exceed USD 1 billion annually. Curatis Holding AG (SIX: CURN) and Neupharma Co., Ltd. (“Neupharma”), a Japanese pharmaceutical company specializing in oncology, immunology, pulmonology and cardiology disorders, today announce an exclusive license and development agreement for corticorelin (C-PTBE-01) in Japan. Under the terms of the agreement, Neupharma will receive exclusive rig
Galderma Completes Successful Placement of EUR 500 Million Eurobond11.3.2026 06:55:00 CET | Press release
Galderma Group AG (SWX:GALD): NOT FOR DISTRIBUTION IN THE UNITED STATES OR IN ANY OTHER JURISDICTION IN WHICH SUCH DISTRIBUTION WOULD BE RESTRICTED BY APPLICABLE LAW OR REGULATION. Galderma Group AG (SIX:GALD), the pure-play dermatology category leader, today announced the successful placement of a single-tranche EUR 500 million Eurobond. The bond has a 5-year maturity and carries a fixed-rate annual coupon of 3.375%. The Eurobond was placed on March 10, 2026, with settlement expected on March 17, 2026, and will be listed on the SIX Swiss Exchange. Citigroup, ING, J.P. Morgan and RBC Capital Markets jointly led the transaction. Net proceeds from the transaction will be used to fully repay Galderma’s existing bank term loan issued in connection with the company’s initial public offering in March 2024. The transaction represents the final step in Galderma’s refinancing process, having obtained two investment grade credit ratings. Galderma is currently rated ‘BBB’ (stable outlook) by Fitc
Estithmar Holding Net Profit Surges 122% to QAR 938 Million; Revenue Rises 54% to QAR 6.4 Billion for the Year Ended 31 December 202510.3.2026 22:52:00 CET | Press release
- Sustainable Growth Driven by International Expansion - Significant Increase Across Key Metrics Estithmar Holding Q.P.S.C. has announced its financial results for the year ended 31 December 2025. The group reported a 54% increase in revenue to QAR 6.4 billion, compared with QAR 4.2 billion in 2024. Gross profit rose to QAR 2.1 billion, up from QAR 1 billion in 2024, representing growth of 111%. EBITDA reached QAR 1.5 billion, an increase of 102% year-on-year. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260310410214/en/ Estithmar Holding Net Profit Surges 122% to QAR 938 Million; Revenue Rises 54% to QAR 6.4 Billion for the Year Ended 31 December 2025 (Photo: AETOSWire) Net profit climbed 122% compared with 2024, reaching QAR 938 million. Earnings per share increased by 145% to QAR 0.264. The growth in net profit was primarily driven by higher revenues, particularly from the specialized contracting and healthcare sectors.
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
